Tag: Food allergy

Omalizumab (brand name Xolair) is a medication used to treat several severe and persistent allergic and inflammatory conditions that have not responded adequately to other treatments. This monoclonal antibody works by targeting and blocking immunoglobulin E (IgE), a key antibody involved in allergic reactions. By reducing IgE, omalizumab can effectively decrease the symptoms and frequency of allergic asthma attacks, hives, and other related issues.

The average elimination half-life of omalizumab is approximately 26 days in patients with asthma and 24 days in patients with chronic spontaneous urticaria [1.2.1, 1.2.5]. This extended half-life allows for infrequent dosing, typically every two or four weeks [1.2.4].

According to the FDA, peanut allergy is one of the most common food allergies and a leading cause of severe allergic reactions. For those wondering what is the name of the peanut drug, the answer is Palforzia (peanut allergen powder-dnfp), an oral immunotherapy designed to help mitigate these reactions. This medication works by gradually exposing the body to controlled amounts of peanut protein to reduce sensitivity over time.

According to the American Academy of Allergy, Asthma & Immunology (AAAAI), antihistamines like Zyrtec are not a substitute for epinephrine in treating severe allergic reactions like anaphylaxis. This crucial fact highlights the misconception that Zyrtec can effectively manage all aspects of a dairy allergy, and the key is understanding its specific function in relieving certain symptoms.

Approximately 36% of medications reviewed in a 2024 study were found to contain dairy-derived excipients, highlighting the importance of knowing what allergy medicine has no dairy in it. For individuals with a severe milk allergy or even high lactose sensitivity, identifying safe options is crucial.

With peanut allergy being one of the most common food allergies in the U.S., affecting millions, the FDA-approved treatment **Palforzia** offers a new option for risk management. This oral immunotherapy helps desensitize patients, mitigating the severity of allergic reactions from accidental exposure to peanut protein.